# Metformin: Discovering Mechanistic Insights and Market Surveillance

Mr. Omkar B. Kamble[1], Mr. Avinash M. Bakle[2], Miss. Bhakti P. Jadhav[3], Miss. Bhakti A. Chitrak[4], Ms. Umme Roman Shaikh[5]
[1,2,3,4]*Student, Sayali Charitable Trust's College of Pharmacy*
[5]*Assistant Professor, Sayali Charitable Trust's College of Pharmacy*

*Abstract*—**Metformin, a biguanide derivative, has long been established as a first-line pharmacotherapeutic agent for type 2 diabetes mellitus (T2DM), yet contemporary research continues to expand its relevance far beyond glycemic control. This literature review synthesizes current findings on metformin's multifaceted mechanisms, clinical applications, and emerging therapeutic potential. Traditionally, metformin's primary mode of action has been attributed to the reduction of hepatic gluconeogenesis and improvements in peripheral insulin sensitivity. Recent studies, however, highlight the involvement of AMP-activated protein kinase (AMPK)–dependent and AMPK-independent pathways, mitochondrial modulation, and alterations in gut microbiota composition, reflecting a complex and evolving pharmacological profile. Metformin, a biguanide derivative, has long been established as a first-line pharmacotherapeutic agent for type 2 diabetes mellitus (T2DM), yet contemporary research continues to expand its relevance far beyond glycemic control. This literature review synthesizes current findings on metformin's multifaceted mechanisms, clinical applications, and emerging therapeutic potential. Traditionally, metformin's primary mode of action has been attributed to the reduction of hepatic gluconeogenesis and improvements in peripheral insulin sensitivity. Recent studies, however, highlight the involvement of AMP-activated protein kinase (AMPK)–dependent and AMPK-independent pathways, mitochondrial modulation, and alterations in gut microbiota composition, reflecting a complex and evolving pharmacological profile. Despite these advances, gaps persist regarding long-term effects, optimal dosing for non-glycemic indications, and population-specific safety considerations, particularly in renal impairment. Overall, the literature portrays metformin as a versatile therapeutic agent with expanding implications, warranting continued research into its mechanisms and broader clinical utility.**

*Index Terms*—**Metformin, type 2 diabetes, AMPK, insulin sensitivity, gluconeogenesis, mitochondrial function, gut microbiota, polycystic ovary syndrome, cancer therapy, metabolic regulation.**

## I. INTRODUCTION

Metformin, a widely used biguanide and cornerstone therapy for type 2 diabetes mellitus (T2DM), has a long and fascinating historical trajectory that informs its current medical relevance. Its origins can be traced back to the medieval use of Galega officinalis (French lilac), a plant known for its hypoglycemic properties due to its active compound guanidine. Although early guanidine derivatives were ineffective or toxic, the development of metformin in the 1950s marked a major breakthrough in safe and durable glucose-lowering therapy. Approved globally over subsequent decades, metformin has since become the first-line pharmacological agent recommended by major diabetes associations due to its efficacy, safety profile, and cost-effectiveness. Pharmacologically, metformin is categorized within the biguanide class, but its multifactorial mechanism of action distinguishes it from other antidiabetic agents. The drug's primary metabolic actions involve the inhibition of hepatic gluconeogenesis, enhancement of insulin sensitivity, and increased peripheral glucose uptake. Historically, the AMP-activated protein kinase (AMPK) pathway was recognized as a central mediator of these effects, but emerging studies highlight additional AMPK-independent mechanisms, including alterations in mitochondrial function, adjustments in cellular redox states, and modulation of the gut microbiome.




Fig. 1: Chemical Structure of Metformin

This rich historical and pharmacological foundation sets the stage for understanding metformin as more than just an antihyperglycemic drug. Its evolving mechanistic insights not only deepen scientific understanding but also broaden the scope of clinical applications. As contemporary research continues to uncover new biological pathways influenced by metformin, it becomes increasingly vital to contextualize its past in order to appreciate its expanding therapeutic future.

Mechanistic Insights: Beyond Glycemic Control

While metformin's glucose-lowering effects have been extensively characterized, recent research has illuminated a complex network of cellular and metabolic pathways influenced by the drug, revealing its far-reaching biological significance. Central among these is the AMPK activation pathway, which plays a crucial role in cellular energy homeostasis. Activation of AMPK leads to reduced hepatic gluconeogenesis, increased fatty acid oxidation, and improved glucose transport all of which contribute to improved metabolic health in individuals with T2DM. However, the recognition of significant AMPK-independent mechanisms marks a paradigm shift in understanding metformin's mechanism of action. One key area of interest is mitochondrial respiration, particularly the inhibition of complex I in the electron transport chain. This inhibition alters the ATP:AMP ratio, triggering numerous downstream metabolic responses. Additionally, metformin impacts lactate production, cytosolic redox balance, and cellular stress response systems, indicating a far more nuanced pharmacodynamic profile than previously recognized. Another rapidly advancing field highlights the drug's influence on the gut microbiota, with evidence suggesting shifts in microbial composition may contribute to improvements in insulin sensitivity and systemic metabolism.

These expanding mechanistic insights underpin metformin's potential applications beyond glycemic regulation, including roles in oncology, reproductive endocrinology, and aging research. The drug's documented effects on cell proliferation, oxidative stress, and inflammatory pathways have opened new avenues of scientific inquiry. Understanding these mechanisms is essential not only for clinical optimization but also for developing targeted treatments that leverage metformin's broad biological activity. Consequently, mechanistic research continues to be a critical driver of metformin's evolving therapeutic landscape.

Clinical Significance and Emerging Therapeutic Applications

Metformin's clinical impact extends far beyond its role as an antihyperglycemic agent. As the first-line therapy for T2DM, its benefits include effective glycemic control, weight neutrality or modest reduction, and a reduced risk of hypoglycemia compared to other pharmacological options. Moreover, long-term studies have demonstrated potential cardiovascular protective effects, making it a foundational drug in diabetes management worldwide. Its favorable safety profile, low cost, and wide availability further reinforce its importance in both developed and resource-limited healthcare settings. Beyond diabetes, metformin has shown significant promise in a variety of non-glycemic conditions. In polycystic ovary syndrome (PCOS), the drug improves insulin resistance, enhances ovulatory function, and has demonstrated benefits on androgen levels. In oncology, epidemiological and preclinical evidence suggests that metformin may exert antiproliferative, pro-apoptotic, and immunomodulatory effects, prompting ongoing clinical trials exploring its role as an adjunct therapy in cancers such as breast, colorectal, and endometrial cancers. Additionally, research into geroscience has highlighted metformin as a potential modulator of aging pathways, including oxidative stress, inflammation, and cellular senescence. These findings position metformin as a candidate for aging-related interventions, though rigorous clinical validation remains necessary.

| Mechanistic Pathway | Description | Physiological Outcome |
|---|---|---|
| AMPK Activation | Metformin increases cellular AMP:ATP ratio, activating AMP-activated protein kinase (AMPK). | ↓ Hepatic gluconeogenesis, ↑ glucose uptake, ↑ fatty acid oxidation. |
| Inhibition of Mitochondrial Complex I | Direct inhibition of complex I in the electron transport chain reduces mitochondrial ATP production. | ↑ AMP levels, altered redox state, decreased hepatic glucose output. |
| Modulation of Gut Microbiota | Enhances beneficial microbes such as Akkermansia muciniphila and alters intestinal glucose and bile acid metabolism. | Improved insulin sensitivity, reduced inflammation, enhanced glucose regulation. |
| Impact on Cellular Redox State | Alters NADH/NAD+ balance and lactate metabolism. | Changes in metabolic signaling and reduced hepatic glucose synthesis. |
| Lysosomal Pathway Interaction | Influences Rag GTPases and lysosomal AMPK activation independent of energy charge. | Enhanced metabolic regulation even without major ATP depletion. |

Table 1: Clinical Significance of Metformin

Variations in population-specific responses, including differing outcomes based on genetic factors, environmental influences, and co-morbid conditions, highlight the necessity for comparative and cross-disciplinary research. Additionally, concerns related to renal function, lactic acidosis risk, and optimal dosing for non-diabetic indications continue to shape clinical guidelines and demand deeper exploration. Despite its widespread use, several challenges remain, including considerations for dosing in renal impairment, uncertainties regarding long-term use in non-diabetic populations, and the need for more robust clinical trials to support emerging indications. As research continues to expand, metformin stands as a versatile and evolving therapy with broad implications for human health. Its growing clinical significance underscores the importance of ongoing review and analysis to inform future applications.

Objectives:

- To explore the historical development and pharmacological foundations of metformin, tracing its evolution from a botanical origin to its establishment as a first-line therapeutic agent for type 2 diabetes mellitus (T2DM).
- To analyze the multifaceted mechanisms of action of metformin, including both AMPK-dependent and AMPK-independent pathways, as well as its effects on mitochondrial function, hepatic gluconeogenesis, and the gut microbiota.
- To critically evaluate clinical evidence supporting metformin's efficacy and safety in the management of T2DM, with emphasis on glycemic control, cardiovascular benefits, long-term outcomes, and population-specific considerations.
- To examine emerging therapeutic applications of metformin beyond diabetes, including its potential roles in oncology, polycystic ovary syndrome (PCOS), reproductive endocrinology, and aging-related research.
- To identify gaps, limitations, and controversies in current metformin research, particularly regarding its non-glycemic uses, long-term safety in diverse populations, and understanding of dosage optimization.
- To provide future research directions that highlight promising areas for scientific advancement, clinical trials, and translational applications aimed at broadening metformin's therapeutic scope.

## II. LITERATURE REVIEW AND DATA COLLECTION

1. One of the most influential mechanistic studies in recent years is by Madiraju, Erion, Rahimi, et al. (2014), who demonstrated that metformin non-competitively inhibits mitochondrial glycerophosphate dehydrogenase (mGPD). Their experiments, conducted in hepatocytes, rat models, and knockout mice, showed that this inhibition leads to a shift in the redox state: increased cytosolic $NADH/NAD^+$ ratio and reduced mitochondrial redox capacity. Functionally, this effect reduced the conversion of lactate and glycerol into glucose, thereby suppressing hepatic gluconeogenesis. Importantly, when mGPD was knocked down by

antisense oligonucleotides in rats or genetically deleted in mice the glucose-lowering effects of metformin were markedly blunted, supporting the centrality of mGPD in this mechanism. This study provided a paradigm shift: rather than purely depending on energy stress (ATP depletion) or AMPK activation, metformin's glucose-lowering effect can be driven via redox-modulated pathways.

2. Building on this, Madiraju et al. (2019) conducted an in vivo study in awake, normal, and diabetic rats to evaluate how metformin (at clinically relevant plasma concentrations) influences gluconeogenesis from various substrates. They found that metformin inhibited gluconeogenesis from lactate and glycerol, but not from pyruvate or alanine, strongly implicating an elevated cytosolic redox state as the mediator of its effect. Remarkably, these effects were independent of changes in energy charge (ATP/ADP ratios) and mitochondrial complex I activity. When the redox state was artificially "normalized" (for example, by infusing methylene blue), the inhibitory impact of metformin on gluconeogenesis diminished, underscoring that redox rather than energy depletion is a primary driver under physiological metformin dosing.
3. Alshawi & Agius (2019) reported that at low therapeutic concentrations, metformin exerts a biphasic effect on the mitochondrial NADH/NAD ratio. Specifically, at very low doses, metformin causes a more oxidized mitochondrial redox state and raises the lactate/pyruvate ratio, but at higher doses it shifts to a more reduced mitochondrial NADH/NAD state potentially reflecting complex I inhibition. Moreover, at these low doses, metformin's suppression of gluconeogenesis from both "oxidized" and "reduced" substrates could not be fully explained by redox shift alone; the authors proposed additional regulation via allosteric modulation of key gluconeogenic enzymes, such as phosphofructokinase-1 (PFK1) or fructose-1,6-bisphosphatase (FBP1). This suggests that metformin's action is more nuanced and may involve multiple overlapping mechanisms.
4. A broader mechanistic framework is provided in a review by Foretz, Guigas, Bertrand, Pollak & Viollet (2014) in Cell Metabolism. They offer an integrative model in which metformin enters hepatocytes (primarily via OCT1 transporters), and inhibits mitochondrial respiratory-chain complex I to some extent, leading to reduced ATP production and accumulation of AMP. The increased AMP can inhibit gluconeogenic enzymes (e.g., FBPase) and adenylate cyclase, thus suppressing the cAMP–PKA signaling pathway. Simultaneously, activation of AMP-activated protein kinase (AMPK) helps to improve lipid metabolism by inhibiting acetyl-CoA carboxylase (ACC), thereby reducing lipogenesis and enhancing fatty acid oxidation. Notably, this review also integrates the mGPD hypothesis by describing how metformin-driven mGPD inhibition can raise cytosolic NADH, limit glycerol-to-glucose flux, and further contribute to reduced hepatic glucose output.
5. This is a definitive, comprehensive review by Traci E. LaMoia and Gerald I. Shulman that examines decades of work on how metformin works at the cellular level. They emphasize that, although the canonical view has long held mitochondrial complex I inhibition and AMPK activation as central, these mechanisms have mostly been demonstrated in suprapharmacological concentrations (millimolar), which may not reflect clinically relevant doses. They highlight a redox-dependent mechanism: at clinically relevant metformin concentrations (≈ 50–100 μM), metformin inhibits mitochondrial glycerol-3-phosphate dehydrogenase (mGPD / GPD2), which alters the cytosolic NADH/NAD^+ ratio, thereby selectively reducing gluconeogenesis from redox-sensitive substrates (e.g., glycerol, lactate). They also systematically categorize gluconeogenesis regulation into four layers: transcriptional, allosteric, substrate availability, and redox; and map how metformin may influence each. Importantly, they caution that many proposed mechanisms (especially complex I inhibition) may not be physiologically relevant in vivo, calling for more work at therapeutic doses. This review is foundational it frames the debate around traditional vs more recent models, and is directly relevant for a mechanistic-insight–focused article. Their discussion of the redox-based mechanism is particularly influential in modern thinking.

6. The review by Madiraju, Erion, Rahimi, et al. takes a "metabolite-centric" approach: instead of focusing purely on signaling (AMPK), the authors analyze changes in gluconeogenic/glycolytic intermediates in response to metformin. They discuss how allosteric regulation (of phosphofructokinase-1, fructose bisphosphatase-1) and other non-AMPK-dependent changes (metabolite levels) could contribute to metformin's suppression of gluconeogenesis. They further propose that in some conditions, metformin lowers hexose monophosphates (like fructose-6-phosphate), which may influence transcriptional regulation of gluconeogenic genes (such as G6pc) indirectly, without necessarily invoking AMPK. This is very relevant for your "mechanistic insights" theme because it underscores that not all effects are mediated by kinase signaling metabolic intermediates themselves (i.e., direct metabolic perturbations) play a strong role.
7. This paper by Domingo-Vidal, García-Ruiz, et al. expands the discussion of metformin beyond its hepatic glucose-lowering activity to vascular / cardiovascular effects. They detail how metformin modulates mitochondrial function, reduces oxidative stress, and decreases leukocyte–endothelium interactions, thereby providing protective effects in the vasculature. They also discuss metformin's influence on AMPK and mTORC1 signaling in vascular tissues, contributing to improved endothelial function. Importantly, they highlight antioxidant effects of metformin arising from complex I modulation, which may contribute to its long-term benefits in cardiovascular disease. Highly relevant for the "market surveillance / pleiotropic effects" part of your review this shows that metformin's benefits are not limited to glycemic control, but also vascular protection.

## III. MECHANISM OF ACTION

1. Cellular Uptake and Distribution:

- Organic cation transporters (OCTs): Metformin is a positively charged molecule that enters hepatocytes (and other cells) primarily via OCT1 (organic cation transporter 1) on the plasma membrane.
- Mitochondrial accumulation: Once inside the cell, metformin accumulates in the mitochondria, driven by the mitochondrial membrane potential (because it is a cation)

2. Inhibition of Mitochondrial Respiratory Chain (Complex I):

- Complex I inhibition: A central and well-characterized mechanism is the partial, mild inhibition of mitochondrial respiratory-chain complex I (NADH: ubiquinone oxidoreductase).
- Energetic stress and AMP/ATP ratio: By inhibiting complex I, metformin reduces mitochondrial ATP production, leading to an increase in the AMP:ATP ratio (or ADP: ATP) within the cell.
- Redox changes: The inhibition also affects NADH oxidation, altering the NAD^+/NADH ratio in the cytosol (because less NADH is reoxidized through the glycerophosphate shuttle).

3. Activation of AMPK (AMP-activated Protein Kinase):

- Energy-sensor activation: The rise in AMP activates AMPK, a key metabolic sensor. Specifically, AMP binding promotes phosphorylation of AMPK at Thr172 by upstream kinases such as LKB1 or CaMKKβ.
- Allosteric activation & protection: AMP has multiple effects: it allosterically activates AMPK, increases its phosphorylation by upstream kinases, and reduces its dephosphorylation by phosphatases.
- Lysosomal pathway (AMP-independent): Intriguingly, at low metformin concentrations, AMPK activation can also occur via a lysosomal mechanism: metformin binds to PEN2 and inhibits v-ATPase, which triggers a complex (AXIN-LKB1) that activates AMPK on the lysosomal surface, independent of large changes in AMP/ATP.
- Downstream AMPK effects:
  a. Phosphorylation (and inhibition) of acetyl-CoA carboxylase (ACC1/ACC2) → reduces lipogenesis and promotes fatty acid oxidation.

b. Suppression of gluconeogenic gene transcription via modulation of CRTC2 (CREB-regulated transcription coactivator 2): AMPK inhibits CRTC2, preventing its nuclear co-activation with CREB-CBP, thereby down-regulating PEPCK and G6Pase.

c. Effects on autophagy: AMPK activation phosphorylates ULK1 and Beclin-1, triggering autophagy, which helps clear lipid droplets ("lipophagy") and mitigates mitochondrial stress.

d. Inflammasome regulation: AMPK can suppress NLRP3 inflammasome activation by decreasing TXNIP (thioredoxin-interacting protein) expression, thereby reducing inflammation.




Fig. 2: Activation of AMPK for the inhibition of Glucose Synthesis

4. AMPK-Independent Mechanisms:

While AMPK activation explains many effects, metformin also exerts AMPK-independent actions, especially in the liver.

- cAMP / Glucagon signaling inhibition: Elevated AMP directly inhibits adenylate cyclase, reducing cAMP production → this suppresses PKA (protein kinase A) signaling downstream of glucagon, thereby lowering gluconeogenesis.
- Allosteric inhibition of fructose-1,6-bisphosphatase (FBP1): AMP can directly inhibit FBP1, a key gluconeogenic enzyme, reducing gluconeogenesis without involving AMPK.
- Inhibition of mitochondrial glycerol-3-phosphate dehydrogenase (mGPD): Metformin inhibits mGPD (GPD2), which is part of the glycerol-3-phosphate shuttle. This impairs the transfer of reducing equivalents from cytosolic NADH into mitochondria, raising cytosolic NADH/NAD^+ ratio, which suppresses gluconeogenesis from glycerol and lactate.
- Redox effect on lactate dehydrogenase (LDH): Because of increased NADH, the LDH equilibrium shifts, reducing conversion of lactate to pyruvate, which further contributes to decreased gluconeogenesis from lactate.
- SHIP2 inhibition: Recent data indicate that metformin inhibits SHIP2 (Src homology 2 domain–containing inositol 5-phosphatase 2), leading to enhanced insulin sensitivity and glucose uptake in peripheral tissues.




Fig. 3: AMPK-Independent mechanisms for the inhibition of Glucose

5. Effects on the Gut and Microbiome:

Metformin's action is not limited to the liver; the gut plays a significant role:

- GLP-1 secretion: It increases GLP-1 (glucagon-like peptide-1) release from intestinal L-cells, and may upregulate GLP-1 receptor expression on pancreatic β-cells, improving insulin secretion sensitivity.
- Microbiome modulation: Metformin alters the composition of gut microbiota (e.g., increasing Akkermansia), which is linked to improved metabolic control and reduced low-grade inflammation in adipose tissue.
- Energy redirection to the gut: Some studies suggest that metformin causes diversion of glucose into the gut, increasing its utilization by intestinal cells and fermentation by microbiota.




Fig. 4: Effects of metformin on the gut

6. Stress Responses, Mitochondrial Quality Control, and Autophagy:

- Mitochondrial ROS and integrated stress response (ISR): By inhibiting complex I, metformin can lead to mild mitochondrial ROS production, triggering an integrated stress response via activation of double-stranded-RNA–activated protein kinase–like ER kinase (PERK) at mitochondria-associated membranes, leading to eIF2α phosphorylation and ATF4 induction.
- Fibroblast growth factor 21 (FGF21): As part of this stress response, ATF4 can increase expression of FGF21, a hormone with metabolic effects.

- Autophagy and mitophagy: Via AMPK activation, metformin promotes autophagy (ULK1/Beclin-1) and mitophagy, helping clear dysfunctional mitochondria, reduce inflammasome activation, and maintain cellular homeostasis.
- Inflammation suppression: Through AMPK-mediated reduction of TXNIP, metformin dampens NLRP3 inflammasome activation, thereby reducing pro-inflammatory cytokine release.




Fig. 4: Effects of metformin on autophagy, inflammasomes and endoplasmic reticulum (ER) stress

7. Effects on Lipid Metabolism and Insulin Sensitivity

- Reduced lipogenesis: Through AMPK, metformin inhibits ACC1/2, decreasing fatty acid and triglyceride synthesis.
- Enhanced fat oxidation: Inhibition of ACC shifts metabolism toward β-oxidation of fatty acids.
- Improved insulin sensitivity: By reducing hepatic diacylglycerol (DAG) levels and other lipid intermediates, metformin enhances insulin signaling in the liver.
- Endothelial effects: Metformin protects vascular endothelial cells via AMPK activation, increasing nitric oxide (NO) production, reducing ER stress, and preventing smooth-muscle proliferation.

## IV. DISCUSSION

Metformin has long been regarded as the cornerstone of type 2 diabetes mellitus (T2DM) management, yet contemporary research continues to illuminate its diverse biological effects and expanding therapeutic relevance. This discussion synthesizes the findings across mechanistic, clinical, and emerging therapeutic domains, providing a cohesive understanding of metformin's multifaceted profile. The literature consistently highlights that the drug's traditional mechanisms, centered on hepatic gluconeogenesis reduction and insulin sensitization, represent only part of a broader metabolic influence that extends across multiple organ systems and cellular pathways.

A major area of consensus across studies is the central role of the AMP-activated protein kinase (AMPK) pathway in mediating metformin's metabolic benefits. Activation of AMPK enhances glucose uptake, increases fatty acid oxidation, and reduces hepatic glucose output effects that are essential to restoring metabolic balance in individuals with T2DM. However, emerging evidence underscores that metformin's actions cannot be fully explained by AMPK alone. Numerous studies have demonstrated AMPK-independent pathways, particularly those involving modulation of mitochondrial complex I, alterations in cellular redox balance, and influences on lysosomal signaling. These findings suggest that metformin exerts broader metabolic effects than previously appreciated and may influence cellular energy metabolism in a more complex, integrated manner. Another compelling dimension of metformin's mechanism is its influence on the gut microbiota. Recent research indicates that metformin alters the composition and functionality of gut microbial populations, enhancing glucose metabolism and reducing systemic inflammation. Changes in specific microbial species, such as Akkermansia muciniphila, have been associated with improved insulin sensitivity and metabolic health. These discoveries highlight the possibility that some of metformin's clinical benefits arise not solely from direct pharmacological action, but also from microbiome-mediated metabolic modulation.

Clinically, metformin remains unmatched in its combination of efficacy, safety, and cost-effectiveness for T2DM treatment. Beyond glycemic control, long-term studies support its modest weight-reducing effects and cardioprotective potential, which is particularly relevant given the high cardiovascular burden in diabetic populations. However, clinical debates persist regarding its use in certain populations, such as those with chronic kidney disease, although updated guidelines and formulations have expanded its safety in these groups. The low risk of lactic acidosis, once a major concern, has been shown to be exceedingly rare when prescribed appropriately. Beyond diabetes, the literature increasingly emphasizes metformin's expanding therapeutic horizon. In polycystic ovary syndrome (PCOS), metformin has demonstrated consistent benefits by addressing underlying insulin resistance, improving ovulation, and reducing hyperandrogenism. Its integration into PCOS treatment guidelines reflects strong evidence supporting both metabolic and reproductive improvements.

Perhaps the most rapidly evolving and debated field is metformin's potential role in cancer therapy. Preclinical studies and observational data suggest that metformin exerts anti-proliferative, pro-apoptotic, and immune-modulating effects. These findings have prompted clinical trials investigating metformin as an adjuvant therapy in cancers such as breast and colorectal cancer. However, results remain mixed, with some studies showing significant benefit and others demonstrating minimal or no effect. Variability in tumor type, genetic background, and metabolic context likely contributes to these inconsistent findings, underscoring the need for more rigorous, well-designed trials. Another emerging area of interest is the role of metformin in aging and longevity. Research suggests that metformin may modulate pathways related to oxidative stress, inflammation, and cellular senescence, all of which contribute to age-related decline. While animal studies and preliminary human research offer promising insights, definitive clinical evidence remains limited. Trials such as TAME (Targeting Aging with Metformin) aim to clarify whether metformin can truly modify the biological aging process, but results are pending.

Despite its wide-ranging therapeutic potential, several limitations and challenges remain. The heterogeneity of study designs and populations makes direct comparisons difficult, and long-term effects in healthy or non-diabetic individuals remain under-explored. Additionally, while mechanistic studies offer compelling hypotheses, many remain unvalidated in clinical settings. Future research must bridge these gaps through more targeted mechanistic experiments and robust, large-scale clinical trials. Overall, the discussion of available literature reveals metformin as far more than a traditional antidiabetic drug. Its broad mechanistic reach and growing therapeutic applications highlight a promising future, but also a need for continued scientific inquiry to fully understand and harness its potential.

## V. CONCLUSION

Metformin remains one of the most extensively studied and clinically valuable pharmacological agents in modern medicine. Originally developed for the management of type 2 diabetes mellitus (T2DM), it has evolved into a drug with far-reaching therapeutic implications that extend well beyond glycemic control. The literature collectively demonstrates that metformin's diverse biological effects arise from a combination of AMPK-dependent and AMPK-independent mechanisms, modulation of mitochondrial function, and significant interactions with the gut microbiota. These multifaceted pathways not only explain its metabolic benefits but also provide a strong scientific foundation for its expanding clinical relevance. Clinically, metformin continues to serve as the first-line therapy for T2DM due to its proven efficacy, safety, and cost-effectiveness. Its additional advantages, including modest weight reduction and potential cardiovascular protection, further support its long-term use across diverse populations. Beyond diabetes, emerging evidence highlights promising roles in polycystic ovary syndrome (PCOS), oncology, and aging-related research, although findings in these areas remain variable and require further validation through high-quality clinical trials.

Despite its broad potential, several gaps persist in the current understanding of metformin's mechanisms and long-term effects, particularly in non-diabetic contexts. Continued research is essential to clarify these uncertainties, optimize dosing strategies, and establish evidence-based applications in new therapeutic domains. In summary, metformin stands as a versatile and impactful drug with a rich history, robust mechanistic foundation, and evolving clinical promise. As scientific exploration continues, it is poised to play an increasingly significant role not only in metabolic health but also in broader fields of medicine.

## REFERENCES

[1] Rena, G., Hardie, D. G., & Pearson, E. R. (2017). The mechanisms of action of metformin. Diabetologia, 60, 1577–1585.

[2] Foretz, M., Guigas, B., Bertrand, L., Pollak, M., & Viollet, B. (2014). Metformin: From mechanisms of action to therapies. Cell Metabolism, 20(6), 953–966.

[3] Pryor, R., & Cabreiro, F. (2015). The microbiome and metformin: Insights for diabetes therapy. Gut Microbes, 6(2), 1–18.

[4] Viollet, B., et al. (2012). Cellular and molecular mechanisms of metformin: An overview. Clinical Science, 122, 253–270.

[5] Zhou, G., Myers, R., Li, Y., et al. (2001). Role of AMP-activated protein kinase in metformin action. Journal of Clinical Investigation, 108(8), 1167–1174.

[6] Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002). Metformin: An update. Annals of Internal Medicine, 137(1), 25–33.

[7] Dowling, R. J. O., Goodwin, P. J., & Stambolic, V. (2011). Understanding the benefit of metformin use in cancer treatment. BMC Medicine, 9, 33–45.

[8] Pernicova, I., & Korbonits, M. (2014). Metformin Mode of action and clinical implications. Nature Reviews Endocrinology, 10, 143–156.

[9] Lord, J. M., Flight, I. H., & Norman, R. J. (2003). Metformin in polycystic ovary syndrome: Systematic review and meta-analysis. BMJ, 327(7421), 951–957.

[10] Buse, J. B., DeFronzo, R. A., Rosenstock, J., et al. (2016). The primary glucose-lowering effect of metformin resides in the gut, not the circulation. Diabetes Care, 39(6), 1–7.

[11] Barzilai, N., Crandall, J. P., Kritchevsky, S. B., & Espeland, M. A. (2016). Metformin as a tool to target aging. Cell Metabolism, 23(6), 1060–1065.

[12] Saisho, Y. (2015). Metformin and inflammation: From mechanisms to clinical implications. Diabetes & Metabolism Journal, 39(5), 312–320.

[13] Madiraju, A. K., Erion, D. M., Rahimi, Y., et al. (2014). Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature, 510, 542–546.

[14] American Diabetes Association. (2023). Standards of Medical Care in Diabetes. Diabetes Care, 46(Suppl. 1), S1–S250.

[15] Vial, G., Detaille, D., & Guigas, B. (2019). Role of mitochondria in the mechanism(s) of action of metformin. Frontiers in Endocrinology, 10, 294.

[16] Flory, J., & Lipska, K. (2019). Metformin in 2019. JAMA, 321(19), 1926–1927.